Immunic
NASDAQ: IMUXNew York, US · Delaware corporation · 5 known investors
Find your way into Immunic
215 people in our graph share verified history with the Immunic team — schools, employers, funds. One of them is your warm intro.
Atsushi Shimadaunlockedknows Andreas Muehler · together at Takeda Pharmaceuticals (overlapped)
×2knows the team · via Duke University - The Fuqua School of Business
×6knows the team · via Humboldt-Universität zu Berlin
knows the team · via The Julius Maximilians University of Würzburg
×2knows the team · via Takeda Pharmaceuticals
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
Founders & leadership
AM
Andreas MuehlerinCo-founderAndreas Muehler is an MD/MBA with more than 30 years of healthcare leadership experience spanning medical devices and pharmaceuticals across the US and Germany, including 10 years as Chief Medical Officer of a NASDAQ-listed biotech company. He has advanced vidofludimus calcium through Phase 3 trials in relapsing multiple sclerosis and established clinical proof of concept for compounds in inflammatory bowel disease and celiac disease.
DV
Daniel VittinCo-founderDaniel Vitt holds a PhD in Organic Chemistry from the University of Würzburg and has worked in biotechnology with expertise in drug development, cheminformatics, and molecular biology. He serves as Chief Executive Officer and Director at Immunic, a biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
IS
INDERPAL SINGHinExecutive
HK
Hella KohlhofinExecutive
PW
Patrick WalshExecutive
AS
Aron SternExecutive
RA
Robert AshleyExecutive
TW
Terry WintersExecutive
EL
JT
Jason TardioChief Operating Officer, President
MP
Michael PanzaraChief Medical Officer
GW
Glenn WhaleyChief Financial Officer
Investors · 5
Reported raises · per SEC filings
Form D private placements$386.8M disclosed across 6 of 7 rounds · 1900–2026
▶$200MraisedMar 2026 · 43 investors · BiotechnologyRule 506(b)
▶$200MraisedMar 2026 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- THORVALD NAGELDirector
- JASON TARDIOExecutive Officer
- TAMAR HOWSONDirector
- GLENN WHALEYExecutive Officer
- INDERPAL SINGHExecutive Officer
- HELLA KOHLHOFExecutive Officer
- PATRICK WALSHExecutive Officer
- ANDREAS MUEHLERExecutive Officer
- BARCLAY PHILLIPSDirector
- DUANE NASHDirector
- SIMONA SKERJANECDirector
- DANIEL VITTExecutive Officer, Director
- RICHARD RUDICKDirector
- JOERG NEERMANDirector
- Offering amount
- $200M
- Amount sold
- $200M
- Sales commissions
- $12M
- Placement agents
- BROOKLINE CAPITAL MARKETS, A DIVISION OF ARCADIA SECURITIES, LLC, Leerink Partners LLC, STIFEL, NICOLAUS & COMPANY, INCORPORATED, GUGGENHEIM SECURITIES, LLC, WILLIAM BLAIR & COMPANY, LLC, LIFESCI CAPITAL LLC, B. RILEY SECURITIES, INC.
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80MraisedJan 2024 · 19 investors · BiotechnologyRule 506(b)
▶$80MraisedJan 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas MuehlerExecutive Officer
- Barclay PhillipsDirector
- Inderpal SinghExecutive Officer
- Daniel VittExecutive Officer, Director
- Patrick WalshExecutive Officer
- Duane NashDirector
- Tamar HowsonDirector
- Jorg NeermannDirector
- Richard RudickDirector
- Glenn WhaleyExecutive Officer
- Maria TornsenDirector
- Hella KohlhofExecutive Officer
- Offering amount
- $240M
- Amount sold
- $80M
- Sales commissions
- $4.8M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedOct 2022 · 14 investors · BiotechnologyRule 506(b)
▶$60MraisedOct 2022 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas MuehlerExecutive Officer
- Vincent OssipowDirector
- Daniel VittExecutive Officer, Director
- Monika Maria TornsenDirector
- Jorg NeermanDirector
- Inderpal SinghExecutive Officer
- Glenn WhaleyExecutive Officer
- Hella KohlhofExecutive Officer
- Patrick WalshExecutive Officer
- Barclay PhillipsDirector
- Tamar HowsonDirector
- Duane NashDirector
- Offering amount
- $60M
- Amount sold
- $60M
- Sales commissions
- $3.6M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.9MraisedMar 2014 · 37 investors · BiotechnologyRule 506(c)
▶$13.9MraisedMar 2014 · 37 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Kameron MaxwellExecutive Officer
- Randolph C. SteerDirector
- Errol R. HalperinDirector
- Andrew HenryExecutive Officer
- Michael V. SwansonExecutive Officer
- Muneer A, SatterDirector
- Andrea LoewenExecutive Officer
- Douglas GodshallDirector
- J. Michael MillisDirector
- Duane NashExecutive Officer
- Aron P. SternExecutive Officer
- Richard MurawskiExecutive Officer
- Terence E. WintersExecutive Officer, Director
- Jean-Jacques BienaimeDirector
- Robert A. AshleyExecutive Officer
- Lowell E. SearsDirector
- Phillip M. CroxfordDirector
- Offering amount
- $13.9M
- Amount sold
- $13.9M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$32MraisedJan 2014 · 62 investors · BiotechnologyRule 506(b)
▶$32MraisedJan 2014 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael V. SwansonExecutive Officer
- Andrea LoewenExecutive Officer
- Errol R. HalperinDirector
- Robert A. AshleyExecutive Officer
- Richard MurawskiExecutive Officer
- Kemeron MaxwellExecutive Officer
- J. Michael MillisDirector
- Douglas GodshallDirector
- Duane NashExecutive Officer
- Andrew HenryExecutive Officer
- Aron P. SternExecutive Officer
- Phillip M. CroxfordDirector
- Jean-Jacques BienaimeDirector
- Terence E. WintersExecutive Officer, Director
- Muneer A, SatterDirector
- Randolph C. SteerDirector
- Lowell E. SearsDirector
- Offering amount
- $32M
- Amount sold
- $32M
- First sale
- Feb 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$929.8KraisedFeb 2012 · 7 investors · BiotechnologyRule 506(b)
▶$929.8KraisedFeb 2012 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phillip CroxfordDirector
- Aron SternExecutive Officer
- J. Michael MillisDirector
- Robert AshleyExecutive Officer
- Terry WintersExecutive Officer, Director
- Randolph SteerDirector
- Offering amount
- $1.5M
- Amount sold
- $929.8K
- Proceeds to insiders
- $108.8K
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06, 46
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$416.3Mvaluation at IPOOct 2014 · $17.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Immunic (IMUX) posts larger Q2 2026 loss but extends cash runway into 2027stocktitan.net · Aug 2026
Immunic (Nasdaq: IMUX) raises $200M, lifts cash to $155M amid higher lossesstocktitan.net · Aug 2026Frequently asked questions
- What does Immunic do?
- Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
- Who founded Immunic?
- Immunic was founded by Andreas Muehler, Daniel Vitt.
- Who are Immunic's investors?
- Immunic's investors include Bayern Kapital, bmp Ventures, Fund+, Pontifax Venture Capital, Omega Funds.
- How much funding has Immunic raised?
- Immunic has disclosed $386.8M raised across 6 of its 7 known rounds.
- Where is Immunic headquartered?
- Immunic is headquartered in New York, US.